Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarecycline for Periorificial Dermatitis
NCT06461299Phase 4Completed
- Sponsor
- Dermatology Institute of Boston
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sarecycline in periorificial dermatitis (POD), sponsored by Dermatology Institute of Boston. Primary endpoint: Percentage of patients with PODSI score 0-2.5 at 4 weeks. Started Jul 2023; status: completed.
02
Drugs
sarecycline
03
Conditions
periorificial dermatitis (POD)
Beyond the preview
Go deeper on NCT06461299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461299.